Missense variants in the voltage-gated sodium channel (VGSC) gene, SCN8A, are linked to earlyinfantile epileptic encephalopathy type 13 (EIEE13). EIEE13 patients exhibit a wide spectrum of intractable seizure types, severe developmental delay, movement disorders, and elevated risk of sudden unexpected death in epilepsy (SUDEP). The mechanisms by which SCN8A variants lead to epilepsy are poorly understood, although heterologous expression systems and mouse models have demonstrated altered sodium current (INa) properties. To investigate these mechanisms using a patient-specific model system, we generated induced pluripotent stem cells (iPSCs) from three patients with missense variants in SCN8A: p.R1872>L (P1); p.V1592>L (P2); and p.N1759>S (P3). Using small molecule differentiation into excitatory neurons, iPSC-derived neurons from all three patients displayed altered INa. P1 and P2 had elevated persistent INa, while P3 had increased resurgent INa compared to controls. Further analyses focused on one of the patients with increased persistent INa (P1) and the patient with increased resurgent INa (P3). Excitatory cortical neurons from both patients had prolonged action potential (AP) repolarization and shorter axon initial segment lengths compared to controls, the latter analyzed by immunostaining for ankyrin-G. Using doxycycline-inducible expression of the neuronal transcription factors Neurogenin 1 and 2 to synchronize differentiation of induced excitatory cortical-like neurons (iNeurons), we investigated network activity and response to pharmacotherapies. Both patient neurons and iNeurons displayed similar abnormalities in AP repolarization. Patient iNeurons showed increased burstiness that was sensitive to phenytoin, currently a standard treatment for EIEE patients, or riluzole, an FDAapproved drug used in amyotrophic lateral sclerosis and known to block persistent and resurgent
Introduction
During the recent explosion in exome sequencing of epilepsy patients, SCN8A was linked to early infantile epileptic encephalopathy type 13 (EIEE13) (Veeramah et al., 2012; Epi4K and Investigators, 2013; Ohba et al., 2014; Larsen et al., 2015) . EIEE13 patients have a wide spectrum of seizure types with seizure onset occurring on average at 5 months of age (Larsen et al., 2015) .
Developmental delays, lack of speech, and hypotonia are nearly universal. Seizures are typically severe in EIEE13 patients, refractory to antiseizure medications (ASMs), and lead to a high risk of sudden unexpected death in epilepsy (SUDEP), findings that have been recapitulated in mouse models (Veeramah et al., 2012; Wagnon et al., 2014; Kong et al., 2015; Larsen et al., 2015; Bunton-Stasyshyn et al., 2019) .
SCN8A encodes the voltage-gated sodium channel (VGSC) a subunit, Nav1.6, that is the most abundant VGSC in the central nervous system, where it is primarily localized to axon initial segments (AIS) and nodes of Ranvier (Gasser et al., 2012) . Nearly all SCN8A variants linked to EIEE13 thus far are de novo missense mutations resulting in single amino acid substitutions (Wagnon and Meisler, 2015) , although one patient inherited the mutation from a mosaic parent (Larsen et al., 2015) . Data from a knock-in mouse model and from heterologous expression of several mutations in cultured cells implicate a variety of potential sodium current (INa) abnormalities in disease pathogenesis, including slowed inactivation kinetics , increased persistent INa (Veeramah et al., 2012; Wagnon et al., 2016; Lopez-Santiago et al., 2017; Ottolini et al., 2017) , and increased resurgent INa Ottolini et al., 2017) .
The predicted outcomes of these changes in INa properties are delayed action potential (AP) repolarization and ectopic firing. Consistent with this, recordings from the Scn8a N1768D/+ EIEE13 mouse model showed early after depolarization (EAD)-like AP waveforms in CA1 hippocampal neurons (Lopez-Santiago et al., 2017) . A complete understanding of SCN8A mutation-specific mechanisms would necessitate the production of multiple mouse models. Moreover, because data from mice often do not translate to humans, it is desirable to test ASM efficacy in other models such as cultured human cortical neurons, which is now feasible in patient-derived cells using induced pluripotent stem cell (iPSC) technology.
While mouse and heterologous systems are useful, we sought to perform mechanistic studies in a human neuronal system that allows rapid testing of potential EIEE13 mutation-specific effects. To this end, we generated iPSC lines from 3 EIEE13 patients. Cortical excitatory patient neurons differentiated from the iPSCs exhibited elevated persistent or resurgent INa compared to control neurons, similar to findings in mouse and heterologous cell culture models. EIEE13 patient neurons also showed prolonged AP repolarization and shorter AIS lengths. To reduce experimental variability inherent in small molecule cortical neuron differentiations, we generated doxycyclineinducible neurons (iNeurons) from the same iPSC lines. iNeurons displayed increased network bursting, as assessed by burst duration and percentage of spikes in bursts. Genotypic differences in network activity were rescued by administration of phenytoin or riluzole, the latter a drug with relative selectivity for persistent and resurgent INa.
Materials and methods

Induced pluripotent stem cell reprogramming
Skin punch biopsies were obtained from 3 EIEE13 patients (P1-3) and two healthy controls (C1 and C4) without known genetic disorders with consent under a protocol approved by the Institutional Review Board of Michigan Medicine and reprogrammed by previously published methods (Tidball et al., 2017) . Two additional control lines used in this study were previously reported as CC1 (now C2) and CHD2 WT/WT2 (now C3) from (Tidball et al., 2016; Tidball et al., 2017) , respectively, and were reprogrammed using identical methods. See Supplemental materials for further details of reprogramming and cell line validation.
CRISPR genome-editing with simultaneous reprogramming
We have previously published methods combining CRISPR genome-editing and iPSC reprogramming (Tidball et al., 2017; Tidball et al., 2018) . See Supplemental materials for further details describing the generation of the P2 rescue iPSC line.
Excitatory neuron differentiation
We utilized a modification of the Shi et al. technique for differentiating iPSCs into excitatory cortical neurons. The neuronal cultures were transduced with lentivirus containing a mouse Camk2a promoter-driven GFP to identify mature neurons (Shcheglovitov et al., 2013; Nehme et al., 2018) . See Supplemental material for further details.
Generation and differentiation of stable doxycycline (dox)-inducible Ngn1/2 (iNeuron) iPSC lines
Established iPSC lines were transfected using Mirus LT-1 with 2 TALEN plasmids (pZT-C13-R1 and pZT-C13-L1, gifts of Jizhong Zou; addgene.org: #52638 and 52637, respectively) targeting the safe-harbor-like locus, CLYBL, and a targeting plasmid containing the dox-inducible promoter system which controls Neurogenin1 (Ngn1) and Ngn2 expression, and constitutively active mCherry (pUCM-CLYBL-Ngn1/2, a gift of Dr. Michael Ward). Pure mCherry+ clonal lines were obtained by manual selection. To differentiate into iNeurons, cells were grown for 72 hours in mTeSR1 media containing doxycycline. Cells were then replated onto PEI/laminin coated dishes in 3N medium containing doxycycline. On day 8, the medium was replaced with BrainPhys medium containing N2 and SM1 supplements as well as BDNF and GDNF. See Supplemental material for further details.
Immunostaining
Neurons grown on Nunc™ Lab-Tek™ III 8-well chamber slides (Thermo Scientific) were fixed in paraformaldehyde for 30 min at room temperature (RT). After permeabilization with 0.2%
Triton-X 100 for 20 min at RT, cells were incubated in PBS containing 5% normal goat serum with 1% BSA and 0.05% Triton-X100 for 1 h at RT. Cell were incubated in primary antibody overnight (see Supplemental Table 2 for antibodies and dilutions) in the same blocking buffer at 4 ºC, washed 4 times in PBS with 0.05% Tween-20 (PBST), and incubated for 90 min with secondary antibody. Cells were washed 3 times in PBST and incubated with bisbenzimide for 5 min. After additional PBS washes, coverslips were mounted on slides with Glycergel mounting medium (Agilent Dako). Images were obtained on a Leica SP5 upright DMI 6000 confocal microscope.
AIS imaging and measurement
Neurons were differentiated and immunostained on day 21 as described above with antibodies for ankyrin-G and microtubule associated protein 2ab-isoforms (MAP2ab). AIS were imaged on a Leica SP5 upright DMI 6000 confocal microscope using a water-immersion 63x objective. Images were taken at 1 Airy unit for the pinhole size with overlapped Z-series steps covering the entire AIS thickness. Max projection images were obtained and exported as TIFF files, then imported into ImageJ. Segmented lines were overlaid by a blinded observer. The plot profiles (intensity of each pixel on the line) were exported and uploaded to a MATLAB program designed for determining AIS length (Dr. Eugene Katrukha at Utrecht University). In short, this program performs a smoothening function, normalizes the intensity data, and applies a threshold of 40% to determine the ends of the AIS (Yau et al., 2014) .
Electrophysiological recordings
Single GFP+ (labeled with a lentiviral Camk2a-GFP reporter) iPSC-derived neurons were analyzed by whole-cell patch clamp recordings. Voltage clamp recordings were performed in the standard whole-cell configuration, using previously described conditions (Liu et al., 2013) . All experiments were carried out at RT (21-22 °C). See Supplemental material for further details.
Multielectrode array (MEA) recordings
On day 3 of dox treatment, differentiating iNeurons were plated onto PEI/laminin coated Axion 96-well MEA recording plates at 1.5 x 10 5 cells in a 5 µL drop on the electrode grid (8 electrodes/well) of each well. Cells were grown as described above with half-volume media changes 3 times/week. Every 2-4 days a 5-min recording was performed at 37 °C after a 5-min equilibration time on the MEA. At 30 days after dox treatment, the MEA plates were used for ASM testing. Due to differences in the overall activity of individual plates, the definition of a network burst was changed from default settings to reduce false positive and false negative network burst detections (Matsuda et al., 2018) . Therefore, we employed an iterative process of altering the minimum percentage of electrodes participating (from 25-50%, or 2-4 electrodes) and the minimum number of spikes (from 10-100 spikes) for each plate on the most active recording day (typically day 30). A maximum interspike interval (ISI) of 75 ms was used to define bursts for all analyses.
Between days 30-33, drug testing was performed on MEA plates that did not show signs of peeling or excessive cell death (shown by loss of overall activity or lack of network bursting in all wells). Concentrated (10x) ASMs were added to the plate in a 10% volume (20 µL) with 1% DMSO, or DMSO alone (control). Thus, final concentrations were 1x of the expected concentration with 0.1% DMSO. Plates were allowed to equilibrate for 5 min on the Maestro MEA followed by a 10-min baseline measurement. The plate was immediately removed, and the drugs were added. Each drug/concentration was added to 1 row yielding 6 wells used per line. The plate was placed back on the MEA and allowed to equilibrate for 5 min followed by a 10-min experimental recording. When performing drug-testing analyses, the percentage of spikes in network bursts values were only used from wells that had a pre-treatment level of at least 5% spikes in network bursts. For all other measures, wells with < 0.01 Hz mean firing rate (MFR) were removed from analyses. Each well of the drug-testing MFR data was normalized to the pretreatment level to account for large plate-to-plate variability in overall activity.
Statistical analyses
Results are expressed as mean ± SEM except for the iNeuron AP dynamics, which are displayed as 95% confidence intervals (CI). Data were analyzed and organized using Excel (Microsoft). Prism (GraphPad) was used for generating graphs and statistical analyses. Sodium current, AIS length, and AP dynamic data were analyzed by the non-parametric Kruskal-Wallis test with uncorrected Dunn's post-test. For MEA data analyses, when no data points were missing, we used repeated measures two-way ANOVA. Post-hoc analyses were performed by two-stage linear stepup procedure for multiple comparison controlling for false discovery rate (Benjamini et al., 2006) .
Results
EIEE13 patient-derived neurons show variant-specific differences in INa properties
To understand the disease mechanisms of individual EIEE13 patient SCN8A variants in a human neuronal model, we generated integration-free iPSCs by episomal transfection of fibroblasts from 3 EIEE13 patients ( Fig. 1A; Table 1 ) and 2 non-epileptic controls, C1 and C4 ( Table 1) . Patient variants were confirmed in each iPSC line by PCR of genomic DNA followed by Sanger sequencing (Supplemental Fig. 1A) . We used two additional control lines, C2 and C3, ( Table 1) that have been previously published (Tidball et al., 2016; Tidball et al., 2017) . Each line used for subsequent experiments was negative for episomal reprogramming vector integration, had no observable genomic abnormalities as tested by either g-band karyotype or SNP chip microarray analyses, and expressed markers of pluripotency ( Supplemental Fig. 1B, C and 
data not shown).
A subset of the iPSC lines (2 patients and 1 control) were differentiated to embryoid bodies, resulting in the formation of 3 germ layers as assessed by immunofluorescence microscopy (Supplemental Fig. 1D ).
We differentiated the iPSCs into cortical excitatory neurons using a dual-SMAD inhibition protocol for specifying PAX6 + neuroepithelium ( Fig. 1B) . Our use of DMH1 for brain morphogenic protein (BMP) inhibition instead of dorsomorphin or Noggin was based on its more specific inhibition of activin receptor-like kinase-2 (ALK2) (Neely et al., 2012) . We also added the Wnt-antagonist XAV939, which is known to increase the forebrain identity of dual-SMAD differentiated neurons (Maroof et al., 2013) , as well as cyclopamine to inhibit any endogenous sonic hedgehog (SHH) signaling and, thereby, decrease the number of subpallial GABAergic neurons generated. Using immunocytochemistry, nearly all patient and control neurons were positive for vesicular glutamate transporter 1 (vGLUT1) with ~10% GABAergic neurons, which often double-labeled with both vGLUT1 and GABA (Fig. 1C, C') , consistent with recent studies that reported several cell types in the rodent brain that co-express these two markers (Perreault et al., 2012; Root et al., 2018) . About 30% of cells expressed CTIP2 at day 43 of differentiation (data not shown), as was reported in the original publication of the protocol we adapted (Shi et al., 2012) .
We also performed qRT-PCR for SCN8A, SCN1A, SCN1B, and SCN4B and found no differences between the patient and control groups (Supplemental Fig. 2) . The mRNA expression for SCN4B was not detectable in our cultures. We next measured INa properties of EIEE13 patient and control iPSC-derived neurons.
Whole-cell voltage clamp recordings were performed on isolated neurons labeled with GFP driven by the Camk2a promoter, a marker of excitatory cortical neurons that has been shown to identify neurons with more mature electrophysiological characteristics ( Fig. 2F) (Shcheglovitov et al., 2013; Nehme et al., 2018) . Representative traces are shown in Fig. 2A pA/pF [n = 8], p = .375) and P2 neurons (3.3 pA/pF [n = 4], p = 0.0706) did not ( Fig. 2K) .
Voltage-dependent properties across the full I-V curve range for a subset of the recorded neurons were not significantly different between genotypes; however, a trend for decreased peak INa (Gmax) for P1 and P3 fits with the significant results found at -30 mV ( Supplemental Table 4 ).
Additionally, there are no differences in inactivation kinetics between controls and patient cells (Supplemental Table 4 ).
Deletion of the P2 pathogenic allele rescues persistent INa
An edited P2 iPSC line was generated using simultaneous CRISPR gene-editing and iPSC reprogramming. The "nickase" Cas9 variant, D10A, was used with two guide RNA sequences that flanked the patient variant. A silent mutation was engineered in the ssODN template to alter one of the PAM sequences to block further nickase breaks. One line with only the wild-type variant was identified; however, the silent mutation was not present (Supplemental Fig. 1A) . Further long-range PCR amplified a ~500 bp deletion of the pathogenic allele (Supplemental Fig. 3 ).
This P2 rescue line, which we call P2r, was differentiated using the same protocol as control and to control levels, we concluded that hemizygous SCN8A expression was not deleterious. Importantly, the elevated percent persistent INa observed in P2 neurons was rescued in the gene edited line, P2r, with values similar to controls but significantly different from P2 (P2r: 2.9 ± 0.9 % [n = 6]; P2: 6.8 ± 1.3 % [n = 10], p = .015; controls: 3.6 ± 0.5 % [n = 24], p = .486, Fig. 2J ).
EIEE13 neurons have EADs and slowed AP repolarization
To investigate changes in neuronal excitability, we recorded spontaneous activity from Camk2a-GFP positive iPSC-derived neurons in current-clamp mode. We observed EADs in P3 neurons, similar to findings in the Scn8a N1768D/+ EIEE13 mouse model (Lopez-Santiago et al., 2017) , but not in neurons from controls, P1 or P2 (Fig. 3A, B and data not shown). We evoked single APs with 1-ms current injections in P1 and P3 neurons. We focused primarily on these two patients because they had the most severe clinical phenotypes and represented both classes of INa abnormalities. Representative traces are depicted in Fig. 3C . P1 neurons showed prolonged repolarization and P3 neurons showed EADs (arrows). Many P1 and P3 neurons did not return to resting membrane potential levels within the duration of the AP recording. Because of this, standard ADP50 and ADP80 measurements could not be accurately determined. Instead, we used 3 time-points following the AP peak (5, 10, and 40 ms) to compare the 3 groups ( Fig. 3E-G) . The resulting peak amplitude values were similar between groups, demonstrating that these measures were appropriate (Fig. 3D) . P1 neuronal APs were more depolarized than controls at 5 and 10 ms, respectively (Fig. 3E, F) . APs in P3 neurons were more depolarized than controls at the 10 and 40 ms time points (Fig. 3F, G) . Passive membrane properties, including resting membrane potential, input resistance, and capacitance, were similar between patients and controls (Supplemental Table 3 ).
EIEE13 patient iPSC-derived neurons have reduced AIS length
Nav1.6, the protein encoded by SCN8A, primarily localizes to the neuronal AIS and nodes of Ranvier via interactions with its binding partner ankyrin-G (Gasser et al., 2012) . To determine whether neurons with EIEE13 variants display AIS alterations, we immunostained for ankyrin-G (Gutzmann et al., 2014) as a proxy for the AIS in iPSC neurons. Nearly all neurons tested contained a single, well-defined AIS (Fig. 4A-C) . We observed a significant decrease in AIS length in neurons derived from all three patient lines compared to controls (Fig. 4D, E) . On average, the AIS length in patient neurons was decreased by 32% (38% for P1, 25% for P2, and 33% for P3) compared to the 3 controls.
EIEE13 patient-derived iNeurons show differences in AP dynamics
We next used the iPSC neuron model for population analyses of neuronal activity and drug screening by MEA recordings. While the dual-SMAD differentiation technique paired with the Camk2a promoter-driven GFP reporter was useful for assessing individual neuron electrophysiology and AIS length, network activity assessed by MEA recordings was highly variable, possibly due to heterogeneous neuronal maturation and variability in the percentage of GABAergic neurons between cultures (data not shown). To reduce variability, we engineered iPSC lines to rapidly and homogeneously generate iNeurons by stably expressing dox-inducible Ngn1 and Ngn2. As previously described, these cells quickly and efficiently differentiate into neurons after dox addition Busskamp et al., 2014; Lam et al., 2017) . Ngn1/2 induction produces neurons expressing upper cortical layer markers, including CUX1, CUX2, and BRN2, but not deeper layer markers like CTIP2 Busskamp et al., 2014; Nehme et al., 2018) . Stable insertion was successfully achieved for P1, P3, C2, and C3 lines using TALENs and homology arms targeting the CLYBL gene that is considered a "safe-harbor-like" locus in the human genome (Cerbini et al., 2015) . We first differentiated iNeurons ( Fig. 5B) and measured evoked APs in single cells by patch clamp methods. APs from patient iNeurons showed reduced repolarization rates, similar to observations in the dual-SMAD neurons (controls: 17.1 ± 3.1 mV/ms [n = 37]; P1: 15.6 ± 3.8 mV/ms [n = 46], p = 0.028; P2: 14.6 ± 3.1 mV/ms [n = 29], p = 0.0038) ( Fig. 5A, F) . In addition, P1 and P3 cells showed increased AP amplitude half-widths compared to controls (controls: 3.08 ± 0.84 ms [n = 37]; P1: 3.56 ± 1.17 ms [n = 46], p = 0.027; P3: 3.48 ± 0.84 mV/ms [n = 29], p = 0.034) ( Fig. 5D) . Finally, P3 neurons exhibited reduced AP peak amplitude and rate of depolarization compared with controls ( Fig. 5C, E) .
Increased burstiness of EIEE13 patient iNeurons
iNeurons were differentiated and plated onto 96-well MEA plates (detailed in Methods and Fig.   5B ) and activity was measured for over a month. Individual raster plots and instantaneous firing frequency plots of neuronal activity on day 33 revealed that EIEE13 network activity, particularly that of P1 neurons, displayed periods of rapid network bursts that become shorter and more frequent with time, followed by a brief period of low activity ( Fig. 6A-C) . Both the increased burst activity and pattern of burst discharges in EIEE13 iNeurons are consistent with an epileptiformlike phenotype. After more than 4 weeks in culture (days 29-33), we found significant increases in measures of bursting activity in patient iNeurons compared to controls, as assessed by burst duration and the percentage of total spikes that were in network bursts for both P1 and P3 (Fig.   6F, G, J, K) (See Methods and materials for burst and network burst criteria). Another measure of burstiness, the coefficient of variation of interspike interval was elevated in P1 only (Fig. 6E,   I ) (Nawrot et al., 2008) . These measures of burstiness were not due to overall increases in firing, given that P1 tended to have lower overall activity compared with controls as measured by the weighted mean firing rate (MFR) and P3 was only slightly elevated (Fig. 6D, H) .
Riluzole and phenytoin attenuate bursting phenotypes in EIEE13 patient iNeurons
We next tested the effects of the ASM phenytoin, which has been used with some success in EIEE13 patients to reduce seizures, as well as riluzole, a drug that has been shown to inhibit persistent and resurgent INa (Urbani and Belluzzi, 2000; Theile and Cummins, 2011) . Riluzole also blocks EAD-like AP wave forms in the Scn8a N1768D/+ EIEE13 mouse model without significant reduction of the rising phase of the AP (Lopez-Santiago et al., 2017) . Drug concentrations were chosen based on patient cerebrospinal fluid data from amyotrophic lateral sclerosis (ALS, riluzole) or epilepsy (phenytoin) patients (Groeneveld et al., 2001; Rambeck et al., 2006) . Experiments included drug concentrations at a half-log above and a half-log below those values, respectively.
In whole-cell patch clamp recordings, 3 µM riluzole completely and reversibly inhibited spontaneous AP firing of P3 neurons (Fig. 7A) . In evoked firing experiments, riluzole did not inhibit the first AP but blocked all subsequent repetitive firing at nearly all current injections (data not shown). Riluzole also increased the voltage threshold for initiating a single AP (Fig. 7B ) of P3 and control neurons.
Acute effects of the drugs were determined by MEA recordings following a 5-minute equilibration time of the drugs in the culture wells. Since the percentage of spikes in network bursts was the most reliable excitability difference for the two patient lines compared to controls (Fig.   6G, K) , we compared the effects of riluzole and phenytoin on this parameter as well as on the MFR. We found that 1 µM riluzole significantly decreased the percentage of spikes in network bursts in patient, but not control, iNeuron cultures ( Fig. 7C, E) . A similar, patient-specific effect was seen with 24 µM phenytoin ( Fig. 7D, F) . Two-way ANOVA analysis from vehicle to therapeutic concentration (1 µM for riluzole and 24 µM for phenytoin) had a significant genotype by treatment interaction (riluzole: p = 0.036, phenytoin: p = 0.035) meaning that the cells responded to both drugs in a genotype-dependent manner. When we plotted the MFR normalized to the pretreatment MFR, we observed a steady decrease in activity with increasing dosage but no differences in the effect of either drug between patient and control (Supplemental Fig. 4) . These results indicate an increased sensitivity of bursting activity in patient iNeurons for both drugs compared to controls, with no genotype-related differential drug effects on overall activity.
Notably, over the concentration range tested, riluzole had a greater inhibitory effect on both percentage of spikes in network bursts (Fig. 7) and overall MFR (Supplemental Fig. 4 ) than phenytoin.
Discussion
Our results demonstrate the utility of iPSC-derived neurons to identify variant-specific INa abnormalities in EIEE13 patients. Of three patients with distinct SCN8A variants studied, cortical-like neurons from two showed increased proportions of persistent INa and one showed increased resurgent INa. All EIEE13 patient neurons had prolonged AP repolarization and decreased AIS lengths. iNeurons generated with the dox-inducible Ngn1,2 system recapitulated the prolonged AP repolarization observed in patient neurons and demonstrated increased network bursting measured by MEA recordings. These recordings provided a platform for testing the VGSC-selective drugs, phenytoin and riluzole. Riluzole administration produced similar effects as phenytoin, one of the most widely used therapies for EIEE13 (Boerma et al., 2016) .
Both drugs reduced network bursting activity at pharmacologically relevant concentrations with some specificity for the disease variant neuronal networks, suggesting that further study of riluzole or riluzole derivatives as an EIEE13 therapy is warranted.
The increase in persistent INa that we identified in human iPSC-derived neurons is consistent with previous studies in other model systems. Elevated persistent INa was reported in the first identified EIEE13 disease variant (N1768>D) modeled in transduced hippocampal neurons (Veeramah et al., 2012) . A mouse model of the N1768>D variant displayed increased persistent INa, slowed repolarization, and EAD-like AP waveforms in CA1 hippocampal neurons (Lopez-Santiago et al., 2017) . Immortalized cells transiently expressing SCN8A cDNA with the N1768>D variant exhibited both increased persistent and resurgent INa , suggesting that the effect of this mutation on INa may be cell type dependent. Here, we found increased persistent INa in patient-derived neuronal cultures expressing two different SCN8A variants. However, unlike P1 (R1872>L) and P2 (V1592>L) neurons, P3 neurons (N1759>S) showed unaltered levels of persistent INa but, instead, showed elevated resurgent INa density. Neurons from P3, but not from P1 or P2, also exhibited EAD-like waveforms during spontaneous firing. A recent study of variants in SCN9A linked to small fiber neuropathy described increased resurgent INa, broader APs, and EADs (Xiao et al., 2019) , similar changes as described here for P3 neurons. These data suggest that elevated resurgent INa may be an underlying mechanism for the development of EAD-like waveforms in some types of mutant neurons.
In addition to the clear differences in INa recorded between patient and control neurons, our hemizygous P2r rescue experiment provides an isogenic control in the absence of the disease variant to demonstrate that the observed increase in persistent INa in P2 neurons is due to the SCN8A de novo variant, rather than to other genetic differences. While haploinsufficiency of some VGSC genes can lead to epilepsy (e.g. SCN1A in Dravet syndrome), heterozygous SCN8A lossof-function in mice results in no overt phenotype, except subtle absence seizures (Papale et al., 2009 ). In fact, the Scn8a med-jo/+ mouse crossed with a Dravet model (Scn1a +/-) resulted in rescue of induced seizure threshold to wild-type levels (Martin et al., 2007) . Taken together, this information and the observation that transient INa was not reduced in P2r neurons suggest that this line is an appropriate rescue for P2 neurons.
The observed reduction in AIS length in EIEE13 patient neurons was unexpected. Others have proposed that AIS shortening is a compensatory mechanism to counter hyperexcitability, and animal models have shown AIS shortening in cortical neurons after TBI or stroke (Baalman et al., 2013; Hinman et al., 2013; Evans et al., 2015) . AIS length is also known to vary with developmental timing and input in the visual cortex (Gutzmann et al., 2014) . More work is necessary to determine whether AIS shortening in EIEE13 neurons reflects a compensatory attempt to decrease hyperexcitability or instead relates to altered development. Interestingly, in terms of the latter possibility, we did not observe AIS shortening in iNeurons (data not shown), which may lose developmental phenotypes observed with small molecule differentiation protocols that more faithfully recapitulate developmental events (Schafer et al., 2019) .
MEA recordings demonstrated increased burstiness in P1 and P3 iNeuron cultures. We used iNeurons to decrease variability by forcing synchronized differentiation into pure excitatory cortical-like neurons. While this approach decreased the variability in our experiments considerably, purely excitatory cultures exhibit spontaneous network burst firing, potentially an epileptiform-like event, under basal conditions (Matsuda et al., 2018) . While both control and patient iNeuron networks exhibited these events, the EIEE13 patient iNeuron networks had greater "burstiness" than controls as measured by longer burst durations and greater percentage of spikes in network bursts. P1 neurons also displayed a greater interspike interval coefficient of variation than controls (Fig. 6F) . These measures suggest increased activity within network bursts, likely due to the cell-intrinsic SCN8A gain-of-function mechanisms we identified using single cell electrophysiological analyses. These differences are similar to changes in network bursts observed following the administration of chemoconvulsants such as bicuculline, pentylentetrazole, and 4aminopyridine (Odawara et al., 2016) . A recent publication investigating Kleefstra syndrome using iNeurons on MEAs identified disease specific alterations using similar outcomes measures, including burst duration, % of spikes out of bursts, and inter-burst-interval coefficient of variation (Frega et al., 2019) . Importantly, EIEE13 patient cultures demonstrated "burst of bursts" events with high-frequency network bursting that did not occur in controls. These events were often followed by reduced activity, resulting in no significant differences in burst frequency calculated over the 5-minute recording period. The reproducible differences in bursting parameters we observed between EIEE13 patient and control neuronal networks allowed us to begin assessing the effects of anti-epileptic drugs.
Currently, the VGSC blocking ASMs, including high-dose phenytoin, are the most effective and commonly used therapies for patients with SCN8A EIEE13 variants (Boerma et al., 2016; Gardella et al., 2018) . However, these drugs frequently cause adverse effects and most EIEE13 patients continue to have frequent seizures despite the use of multiple ASMs (Braakman et al., 2017) . We chose to examine a VGSC-selective inhibitor not currently used for epilepsy, riluzole, for its potential to more specifically attenuate persistent and resurgent INa than phenytoin.
Riluzole is used for the treatment of ALS and is known to inhibit INa by binding to and stabilizing the inactive state of VGSC a subunits (Song et al., 1997) . Riluzole has also been shown to preferentially inhibit both persistent and resurgent INa (Urbani and Belluzzi, 2000; Spadoni et al., 2002; Theile and Cummins, 2011; Xie et al., 2011) . Even though riluzole has been used to effectively inhibit seizures in mice, rats, and baboons, it has not been used to treat epilepsy patients (Mizoule et al., 1985; Romettino et al., 1991; Doble, 1996; De Sarro et al., 2000; Yoshida et al., 2001) . Although riluzole affects a wide array of channels and receptors, at the concentrations found in patients and tested in our MEA recordings (<10 µM), riluzole is thought to selectively inhibit persistent INa and potentiate calcium-dependent potassium currents (Bellingham, 2011) .
Application of either phenytoin or riluzole in concentrations reflecting patient CSF concentrations identified in the literature resulted in a variant-specific reduction in burstiness parameters to control levels (Groeneveld et al., 2001; Rambeck et al., 2006) . Thus, our drug-testing platform is informative at treatment-relevant concentrations.
Patients 1, 3, and 4 experienced medically refractory seizures despite using standard VGSC blocking (including phenytoin, carbamazepine, oxcarbazepine, lamotrigine, etc) and other ASMs.
The mutation position in the NaV1.6 channel may be, in part, why VGSC-blocking drugs were ineffective in patients 3 and 4 ( Table 1 ). Previous work showed that the SCN2A/Nav1.2 variants N1769>A and V1767>A (among others on segment IVS6) altered the effectiveness of etidocaine on INa (Ragsdale et al., 1994) . The equivalent residues in Nav1.6 are N1759 (mutated in P3) and V1757 (mutated in P4). Neither patient had adequate seizure relief with typical ASMs -phenytoin, lamotrigine, and carbamazepine -that are thought to interact at this same site (Lipkind and Fozzard, 2010) . Riluzole, on the other hand, has a theoretical binding pocket interacting with residues 1787, 1801, and 1845 of NaV1.6 (Bello et al., 2012) . These observations demonstrate that further studies are needed to assess the efficacy and safety of riluzole treatment in EIEE13.
Although it should be noted that riluzole has been well tolerated by children with spinal muscular atrophy and obsessive-compulsive disorder (Russman et al., 2003; Grant et al., 2014) . Importantly, the findings by our group in patient-derived neurons and others in heterologous systems/cultured neurons Wagnon et al., 2016) of mutation-specific gain-of-function effects in EIEE13 suggests that the ASM choice may be variant-specific. The patient-derived neuronal models that we describe offer a useful approach for this type of precision epilepsy therapy. 
